Needham & Company Reiterates Generation Bio (GBIO) at Buy with $27 PT, "Technology Has Potential to Overcome Key Obstacles in Gene Therapy... Generation is a Potential Acquisition Target"
Tweet Send to a Friend
Needham & Company analyst Gil Blum reiterated a Buy rating and $27.00 price target on Generation Bio (NASDAQ: GBIO), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
